Tom J.G. Gevers

2.7k total citations
58 papers, 1.2k citations indexed

About

Tom J.G. Gevers is a scholar working on Genetics, Epidemiology and Surgery. According to data from OpenAlex, Tom J.G. Gevers has authored 58 papers receiving a total of 1.2k indexed citations (citations by other indexed papers that have themselves been cited), including 39 papers in Genetics, 24 papers in Epidemiology and 15 papers in Surgery. Recurrent topics in Tom J.G. Gevers's work include Genetic and Kidney Cyst Diseases (37 papers), Liver Disease Diagnosis and Treatment (21 papers) and Cystic Fibrosis Research Advances (14 papers). Tom J.G. Gevers is often cited by papers focused on Genetic and Kidney Cyst Diseases (37 papers), Liver Disease Diagnosis and Treatment (21 papers) and Cystic Fibrosis Research Advances (14 papers). Tom J.G. Gevers collaborates with scholars based in Netherlands, United States and Belgium. Tom J.G. Gevers's co-authors include Joost P.H. Drenth, Wietske Kievit, Marten A. Lantinga, Christoph Schramm, Marie C. Hogan, Myrte K. Neijenhuis, Vicente E. Torres, Frederik Nevens, Simon Pape and Melissa Chrispijn and has published in prestigious journals such as SHILAP Revista de lepidopterología, Gastroenterology and Hepatology.

In The Last Decade

Tom J.G. Gevers

53 papers receiving 1.2k citations

Peers

Countries citing papers authored by Tom J.G. Gevers

Since Specialization

Citations

This map shows the geographic impact of Tom J.G. Gevers's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Tom J.G. Gevers with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Tom J.G. Gevers more than expected).

Fields of papers citing papers by Tom J.G. Gevers

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Tom J.G. Gevers. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Tom J.G. Gevers. The network helps show where Tom J.G. Gevers may publish in the future.

Co-authorship network of co-authors of Tom J.G. Gevers

This figure shows the co-authorship network connecting the top 25 collaborators of Tom J.G. Gevers. A scholar is included among the top collaborators of Tom J.G. Gevers based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Tom J.G. Gevers. Tom J.G. Gevers is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Diastolic dysfunction as predictive parameter for the development of post-TIPS cardiac decompensation 2025 ·International Journal of Cardiology ·(unknown), Tom J.G. Gevers, (unknown), Jos Habets, Anne G. Raafs, Jerremy Weerts, Stéphane Heymans, Christiaan van der Leij, Michiel de Haan, Job A.J. Verdonschot, Matthijs Kramer, (unknown)	1
2	Phosphatidylethanol and ethyl glucuronide to categorize alcohol consumption in alcohol-related cirrhosis 2025 ·JHEP Reports ·(unknown), Catalina Dumitrascu, Nele Van den Eede, Hugo Neels, Hannah van Malenstein, Tom J.G. Gevers, Matthijs Kramer, (unknown), Ad Masclee, Douwe de Boer, Van der Merwe, Frederik Nevens, Alexander L.N. van Nuijs, Jef Verbeek	2
3	What do patients and informal caregivers value in IBD care? A narrative inquiry 2025 ·BMC Health Services Research ·(unknown), (unknown), Zlatan Mujagic, (unknown), Marin J. de Jong, Tom J.G. Gevers, (unknown), (unknown), (unknown), (unknown), Merel Kimman, Stephanie M C Ament, Marieke Pierik	0
4	Mice infected with M . tuberculosis with Rv0678 mutations still benefit from bedaquiline treatment 2024 ·SHILAP Revista de lepidopterología ·Nacer Lounis, Tom J.G. Gevers, Cristina Villellas, (unknown)	0
5	The pathophysiology of polycystic liver disease 2024 ·Journal of Hepatology ·(unknown), (unknown), Tom J.G. Gevers, Joost P.H. Drenth	3
6	P093 Innovating in IBD care: what do patients and informal caregivers value? Preliminary results of a narrative inquiry 2024 ·Journal of Crohn s and Colitis ·Bjørn Thomassen, (unknown), Zlatan Mujagic, Feikje Smeets, Marin J. de Jong, Tom J.G. Gevers, (unknown), (unknown), Gerard Dijkstra, Stephanie M C Ament, Marie J. Pierik	1
7	Expanding the clinical application of the polycystic liver disease questionnaire: determination of a clinical threshold to select patients for therapy 2023 ·HPB ·Thijs R.M. Barten, (unknown), Marie C. Hogan, Tom J.G. Gevers, Joost P.H. Drenth	2
8	Research gaps and opportunities in autoimmune hepatitis—Results of the international autoimmune hepatitis group research workshop 2022 2023 ·Liver International ·Romée J.A.L.M. Snijders, David N. Assis, Ye Htun Oo, Marcial Sebode, Richard Taubert, José Willemse, (unknown), Ansgar W. Lohse, Joost P.H. Drenth, Tom J.G. Gevers, (unknown)	10
9	Importance of complete response for outcomes of pregnancy in patients with autoimmune hepatitis 2023 ·Liver International ·(unknown), (unknown), Maarten E. Tushuizen, Ynto S. de Boer, (unknown), Robert A. de Man, Johannes T. Brouwer, Johan P. Kuyvenhoven, Michael Klemt‐Kropp, Tom J.G. Gevers, Eric T.T.L. Tjwa, Edith M.M. Kuiper, M.A.M.T. Verhagen, Philip W. Friederich, Bart van Hoek	5
10	Health-related quality of life in autoimmune hepatitis 2021 ·World Journal of Hepatology ·Romée J.A.L.M. Snijders, Piotr Milkiewicz, Christoph Schramm, Tom J.G. Gevers	11
11	Predniso(lo)ne Dosage and Chance of Remission in Patients With Autoimmune Hepatitis 2019 ·Clinical Gastroenterology and Hepatology ·Simon Pape, Tom J.G. Gevers, (unknown), (unknown), Jan Maarten Vrolijk, Bart van Hoek, Gerd Bouma, Carin M.J. van Nieuwkerk, Johannes Hartl, Christoph Schramm, Ansgar W. Lohse, Richard Taubert, Elmar Jaeckel, Michael P. Manns, Mária Papp, Felix Stickel, Michael A. Heneghan, Joost P.H. Drenth	45
12	Development and Validation of a Patient-Reported Outcome Measurement for Symptom Assessment in Cirrhotic Ascites 2018 ·The American Journal of Gastroenterology ·Myrte K. Neijenhuis, Tom J.G. Gevers, Thomas D. Atwell, (unknown), (unknown), Wietske Kievit, Joost P.H. Drenth, Patrick S. Kamath	9
13	Symptom relief and not cyst reduction determines treatment success in aspiration sclerotherapy of hepatic cysts 2018 ·European Radiology ·Myrte K. Neijenhuis, (unknown), Wietske Kievit, Maxime Ronot, Tom J.G. Gevers, Joost P.H. Drenth	12
14	The Association of Combined Total Kidney and Liver Volume with Pain and Gastrointestinal Symptoms in Patients with Later Stage Autosomal Dominant Polycystic Kidney Disease 2017 ·American Journal of Nephrology ·Hedwig M. A. D‘Agnolo, Niek F. Casteleijn, Tom J.G. Gevers, Johan W. de Fijter, Maatje D.A. van Gastel, (unknown), Dorien J.M. Peters, Mahdi Salih, Darius Soonawala, Edwin M. Spithoven, Folkert W. Visser, Jack F.M. Wetzels, Robert Zietse, Ron T. Gansevoort, Joost P.H. Drenth	12
15	The effect of disease severity markers on quality of life in autosomal dominant polycystic kidney disease: a systematic review, meta-analysis and meta-regression 2017 ·BMC Nephrology ·Myrte K. Neijenhuis, Wietske Kievit, Ronald D. Perrone, Jeff A. Sloan, Patricia J. Erwin, M. Hassan Murad, Tom J.G. Gevers, Marie C. Hogan, Joost P.H. Drenth	17
16	Full-dose sofosbuvir and daclatasvir for chronic hepatitis C infection in haemodialysis patients. 2016 ·Data Archiving and Networked Services (DANS) ·Tom J.G. Gevers, David M. Burger, (unknown), M. P. Kooistra, Clemens Richter	9
17	1386 EVEROLIMUS DOES NOT FURTHER REDUCE POLYCYSTIC LIVER VOLUME WHEN ADDED TO LONG ACTING OCTREOTIDE: RESULTS FROM A RANDOMIZED CONTROLLED TRIAL IN POLYCYSTIC LIVER DISEASE PATIENTS 2013 ·Journal of Hepatology ·Melissa Chrispijn, Tom J.G. Gevers, Jeroen Hol, René Monshouwer, Helena M. Dekker, Joost P.H. Drenth	5
18	Young Women With Polycystic Liver Disease Respond Best to Somatostatin Analogues: A Pooled Analysis of Individual Patient Data 2013 ·Gastroenterology ·Tom J.G. Gevers, Joanna IntHout, Anna Caroli, Piero Ruggenenti, Marie C. Hogan, Vicente E. Torres, Frederik Nevens, Joost P.H. Drenth	61
19	Rationale and design of the RESOLVE trial: lanreotide as a volume reducing treatment for polycystic livers in patients with autosomal dominant polycystic kidney disease 2012 ·BMC Nephrology ·Tom J.G. Gevers, Melissa Chrispijn, Jack F.M. Wetzels, Joost P.H. Drenth	11
20	Somatostatin analogues for treatment of polycystic liver disease 2010 ·Current Opinion in Gastroenterology ·Tom J.G. Gevers, Joost P.H. Drenth	30

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact